In:
Oncology, S. Karger AG, Vol. 81, No. 3-4 ( 2011), p. 273-280
Abstract:
〈 i 〉 Objective: 〈 /i 〉 The aim of the present study was to retrospectively assess the safety and efficacy of the combination of gemcitabine and nedaplatin in elderly patients with advanced non-small-cell lung cancer (NSCLC). 〈 i 〉 Methods: 〈 /i 〉 Patients ≧75 years with previously untreated NSCLC who underwent chemotherapy consisting of gemcitabine (800 mg/m 〈 sup 〉 2 〈 /sup 〉 on days 1 and 8) and nedaplatin (80 mg/m 〈 sup 〉 2 〈 /sup 〉 on day 1) every 3 weeks were retrospectively analyzed. 〈 i 〉 Results: 〈 /i 〉 Of the 35 patients, 28 were men and 7 were women, with a mean age of 78 years (range 75–87); 10 patients had stage IIIB disease and 25 patients had stage IV disease. The overall response rate was 45.7% (95% confidence interval 28.8–63.4). The median survival time was 14 months (range 3–44). Grade 3–4 toxicities included neutropenia in 74.3%, thrombocytopenia in 48.6%, anemia in 34.3%, hepatic dysfunction in 11.4%, and infection in 2.9%. There were no treatment-related deaths. There were no differences in response rate and survival between patients aged 75–79 years and patients ≧80 years, although grade 3–4 thrombocytopenia and anemia were significantly more frequent in patients ≧80 years. 〈 i 〉 Conclusion: 〈 /i 〉 Our results suggest that the combination of gemcitabine and nedaplatin is effective and well tolerated for selected elderly patients with advanced NSCLC.
Type of Medium:
Online Resource
ISSN:
0030-2414
,
1423-0232
Language:
English
Publisher:
S. Karger AG
Publication Date:
2011
detail.hit.zdb_id:
1483096-6
detail.hit.zdb_id:
250101-6
Permalink